Paradoxically, we found that patients with a higher expression of CRY1 in their tumours showed lower OS and DFS, probably because these patients also showed an increased risk of developing MM at 3 and 5 years after diagnosis of the disease, which could be used as an advantage for the management of these patients. This evidence concerns the gene CRY1 and Miyoshi myopathy.